1. Japan Stocks

  2. •

    Commercial services

  3. •

    Advertising/Marketing services
GMO TECH Holdings, Inc.

GMO TECH Holdings, Inc.

TTSE:415A
5,520.00
JPY
-100.00
(-1.78%)
7.40BMarket Cap
GMO TECH Holdings, Inc.
TSE:415A
(Tokyo Stock Exchange)

Recent

price

5,520.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
JPY
2,369.92
3,012.39
3,126.39
2,676.56
2,656.08
2,634.77
2,456.44
2,541.71
4,007.54
5,142.32
5,896.45
6,436.56
5,686.28
- -
Revenue per Share
114.62
156.78
200.04
7.03
44.93
-165.84
129.63
13.25
-271.44
-278.04
381.72
626.97
1,264.08
- -
Basic EPS, GAAP
126.98
116.15
248.82
-83.13
192.66
-106.73
4.2
-106.51
-208.29
-152.69
210.18
259.6
30.39
- -
Free Cash Flow per Basic Share
36.55
51.28
51.85
71.78
0.06
30.36
0.12
67.9
0.05
- -
- -
199.62
280.08
- -
Dividend per Share
192.35
773.9
921.35
797.4
843.93
651.47
783.86
727.42
455.23
370.41
757.29
1,150.61
2,532.4
2,440.07
Book Value per Share
187.73
765.19
911.97
796.88
843.8
650.39
782.53
598.81
127.24
344.96
617.3
921.62
2,279.03
1,814.22
Tangible Book Value per Share
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Basic Weighted Avg Shares
2,370
3,030
3,439
2,867
2,819
2,796
2,607
2,697
4,252
5,456
6,256
6,868
6,923
- -
Sales/Revenue/Turnover
16.61
17.64
20.5
13.32
3.71
-3.42
0.86
0.62
-6.07
4.14
9.05
13.09
7.51
- -
Operating Margin (%)
2
5
8
14
3
19
5
11
55
48
15
36
76
- -
Depreciation Expense
115
158
220
8
48
-176
138
14
-288
-295
405
669
1,539
- -
Net Income, GAAP
38.04
39.61
38.02
52.63
45.17
- -
18.67
25.66
- -
- -
27.94
29.43
5
- -
Effective Tax Rate (%)
4.84
5.2
6.4
0.26
1.69
-6.29
5.28
0.52
-6.77
-5.41
6.47
9.74
22.23
- -
Profit Margin (%)
182
812
944
708
756
561
687
528
97
556
735
1,035
2,993
2,170
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
90
280
210
140
90
86
LT Debt
212
851
1,013
846
896
691
832
772
483
393
806
1,221
3,998
3,852
Total Equity
- -
27.17
20.65
1.56
6.23
- -
2.36
1.52
- -
- -
41.16
44.93
17.14
- -
Return on Invested Capital (%)
- -
29.67
23.6
0.81
5.47
- -
18.06
1.75
- -
- -
44.52
53.33
55.08
- -
Return on Capital (%)
- -
29.67
23.6
0.81
5.47
-22.18
18.06
1.75
-45.9
-67.35
67.56
66.01
58.98
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Jun'24
Mar'26
Jun'26
ST Debt
70
- -
99
LT Borrowings
175
- -
86
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1
2
2
Market Capitalization
- -
8,020
7,396

Working Capital

JPY

•

in mil. unless spec.
Jun'24
Mar'26
Jun'26
Total Current Assets
2,254
- -
4,022
Cash, Cash Equivalents & STI
1,149
- -
2,541
Accounts Receivable, Net
949
- -
1,189
Inventories
- -
- -
- -
Total Current Liabilities
1,383
- -
1,852
Payables & Accruals
- -
- -
- -
ST Debt
70
- -
99
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
30.76%
65.59%
227.44%
Free Cash Flow
-358.71%
-46.24%
-86.64%
Net Income, GAAP
-248.88%
-437.63%
130.04%
Sales/Revenue/Turnover
8.88%
22.25%
0.8%
Total Cash Common Dividend
- -
- -
60.09%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,874
1,820
- -
- -
6,868
2025
- -
- -
- -
- -
6,923
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
181.97
165.66
- -
- -
626.97
2025
- -
- -
- -
- -
1,264.08
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
199.62
2025
- -
- -
- -
- -
280.08
2026
- -
- -
- -
- -
- -
Similar Companies
Sharplink, Inc. (NASDAQ:SBET)
Trump Media & Technology Group Corp. (NASDAQ:DJT)
Veritone, Inc. (NASDAQ:VERI)
PT Era Media Sejahtera Tbk (IDX:DOOH)
Kuaishou Technology Class B (HKEX:1024)
U-BX Technology Ltd. (NASDAQ:UBXG)
Business
GMO TECH Holdings, Inc. engages in the design, development, and sale of genetic engineering, biotechnology, and related technology tools and services. The company focuses on high-throughput molecular biology platforms, genome editing technologies, and analytical software that enable researchers and institutions to perform genetic modification, construct libraries, and analyze genomic data. Its product suite includes gene editing reagents, genomic engineering kits, cell line generation tools, and associated consumables; software and analytics platforms for design, simulation, data management, and result interpretation; and professional services such as project design, optimization support, and training. Latest major changes and strategic developments include recent partnerships and strategic alliances with research institutions and biotechnology firms to co-develop and commercialize next-generation genome editing capabilities; funding rounds or acquisitions that expand technology breadth and geographic reach, including investments in platform integration and analytics capabilities; new product launches and service offerings that broaden application areas in synthetic biology, functional genomics, and precision medicine; organizational restructuring or rebranding to align corporate identity with expanded product scope; and operational enhancements aimed at scaling manufacturing, expanding regional sales coverage, and accelerating go-to-market activities over the past 1–2 years. Additional context: operates in the biotechnology and life sciences equipment and services segments; targets academic, pharmaceutical, and contract research organizations; geographic operations span Japan and international markets; founded in 200X with headquarters in Japan; maintains subsidiaries or parent relationships as part of a broader corporate group structure.